PDCD1 and neoplasm: At present, numerous studies have shown that blocking the PD-L1/PD-1 pathway shows significant anti-tumor effects in patients with advanced cancer, and is considered to be the standard for the development of the new immune checkpoint blockade (ICB) and combination therapy [46].